Anita Rijneveld
Anita Rijneveld received her medical degree in 1997 at the University of Amsterdam in Amsterdam and in 2005 completed her training in Internal Medicine and Hematology at the Amsterdam Medical Center (AMC, currently known as Amsterdam UMC) under supervision of Prof Dr P. Speelman and Prof Dr M. van Oers.
She received her PhD degree in 2005. With her thesis about Pneumococcal pneumonia at the department of Infectious diseases, also at the AMC.
Our research
Acute lymphoblastic leukemia (ALL)
Her clinical research focusses on introduction of new concepts in first line treatment in adults with ALL (see HOVON). Translational research concerning prognostication and deciphering genetic subsets in adult ALL coupled with these trials is also her focus (together with bioinformatics). She is the chair of the European Working group of ALL (EWALL), the head of the ALL working group of HOVON and chairs the Dutch guidelines committee.
Hemoglobinopathies (HBP)
Dr Rijneveld is head of the center of expertise for hemoglobinopathies and local PI of numerous clinical trials. She is member of the Sickle Cell Outcome research (SCORE) consortium and Landelijke Werkgroep HBP Behandelaren (LWHB) and participates in European reference network on red blood cell disorders (ERN). She also chairs the Dutch guidelines committee for sickle cell disease and a member of the committee for Dutch guidelines on thalassemia.
Relevant websites
- Patiëntenfolder Sikkelcentrum kinderen en volwassenen
- Sikkelcelziekte & Thalassemie Netwerk
Our team
Hemoglobinopathies (HBP)
Anita Rijneveld, hematologist
Minke Rab, hematologist
Aida Kidane Grebemeskel, PhD student
Acute lymphoblastic leukemia (ALL)
Jurjen Versluis, hematologist
Nick Wlazlo, hematologist
Vincent van der Velden, immunologist
Remco Hoogenboezem, bioinformatician
Mathijs Sanders, bioinformatician
Eske van Baalen, PhD student
Rosan Olsman, PhD student (in cooperation with immunology)
Aniko Szabo, PhD student
Key publications
Acute lymphoblastic leukemia (ALL)
Roger Mulet-Lazaro, Anikó Sijs-Szabó, Remco M Hoogenboezem, Stanley van Herk, Carla Exalto, Jasper E Koenders, Patricia G Hoogeveen, François G Kavelaars, Anita M Schelen, Willemijn van den Ancker, Arjan A van de Loosdrecht, Charles G Mullighan, H Berna Beverloo, Vincent van der Velden, Jan J Cornelissen, Peter J M Valk, Anita Rijneveld , Mathijs A Sanders. Transcriptional profiling directs the classification of acute leukemias of ambiguous lineage into AML, B-ALL, or T-ALL. Hemasphere. 2025 Aug 19;9(8)
Jabbour E, Lussana F, Martínez-Sánchez P, Torrent A, Rifón JJ, Agrawal V, Tormo M, Cassaday RD, Cluzeau T, Huguet F, Papayannidis C, Hernández-Rivas JM, Anita Rijneveld, Fleming S, Vucinic V, Böll B, Ikezoe T, Abdul-Hay M, Savoie ML, Schuh AC, Berthon C, Schwartz S, Chiaretti S, Yuda J, Miyazaki T, González-Campos J, Chen Y, Wong H, Choudhry J, Zugmaier G, Guest E, Gordon P, Kantarjian H. Subcutaneous blinatumomab in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: post-hoc safety and activity analysis from a multicentre, single-arm, phase 1/2 trial. Lancet Haematol. 2025 Jul;12(7):e529-e541.
Ghobadi A, Aldoss I, Maude SL, Bhojwani D, Wayne AS, Bajel A, Dholaria B, Faramand RG, Mattison RJ, Anita Rijneveld, Zwaan CM, Calkoen FG, Baruchel A, Boissel N, Rettig MP, Wood B, Jacobs K, Christ S, Irons H, Capoccia B, Masters D, Gonzalez J, Wu T, Del Rosario M, Hamil A, Bakkacha O, Muth J, Ramsey B, McNulty E, Baughman J, Cooper ML, Davidson-Moncada JK, DiPersio JF. Phase 1/2 Trial of Anti-CD7 Allogeneic WU-CART-007 in patients with Relapsed/Refractory T-cell Malignancies. Blood. 2025 May 30:
Hermans SJF, van Norden Y, Versluis J, Anita Rijneveld, van der Holt B, de Weerdt O, Biemond BJ, van de Loosdrecht AA, van der Wagen LE, Bellido M, van Gelder M, van der Velden WJFM, Selleslag D, van Lammeren-Venema D, van der Velden VHJ, de Wreede LC, Postmus D, Pignatti F, Cornelissen JJ. Benefits and risks of clofarabine in adult acute lymphoblastic leukemia investigated in depth by multi-state modeling. Cancer Med. 2024 May;13(9):e6756
van Outersterp I, Boer JM, van de Ven C, Reichert CEJ, Boeree A, Kruisinga B, de Groot-Kruseman HA, Escherich G, Sijs-Szabo A, Anita Rijneveld, den Boer ML. Tyrosine kinase inhibitor resistance in de novo BCR::ABL1-positive BCP-ALL beyond kinase domain mutations. Blood Adv. 2024 Apr 23;8(8):1835-1845
Hemoglobinopathies (HBP)
Sigrid van der Veen, Judith J M Jans, Eduard J van Beers, Bart J Biemond, Pablo Bartolucci, Maria Paola Boaro, Anna Collado Gimbert, Raffaella Colombatti, Mirco D'Agnolo, Karin J Fijnvandraat, Amira Idrizovic, Petros Kountouris, Mar Mañú Pereira, Elisabetta Mezzalira, Minke A E Rab, Anita Rijneveld, Tiziana Sanavia, Nanda M Verhoeven-Duif, Marjon H Cnossen. Metabolomics in sickle cell disease: Current knowledge and gaps - A scoping review. Blood Rev. 2025 Sep 6:101338.
Traets MJM, Bos JF, van der Veen S, van Pelt L, van Dijk MJ, van Oirschot BA, de Wilde JRA, Jans JJ, van Solinge WW, Schols SEM, Lauw MN, Cnossen MH, Nur E, Biemond BJ, Anita Rijneveld, van Beers EJ, van Wijk R, Rab MAE. Pyruvate Kinase Function Correlates With Red Blood Cell Properties and Clinical Manifestations in Sickle Cell Disease. Am J Hematol. 2025 May;100(5):785-796
Kidane Gebremeskel AS, Rab MA, van Werkhoven ED, Petersen TB, Cnossen MH, M'charek A, Meeks KAC, Anita Rijneveld. The use of race and ethnicity in sickle cell disease research. BMC Med Res Methodol. 2025 Mar 7;25(1):63
van Dijk MJ, Ruiter TJJ, van der Veen S, Rab MAE, van Oirschot BA, Bos J, Derichs C, Anita Rijneveld, Cnossen MH, Nur E, Biemond BJ, Bartels M, Schutgens REG, van Solinge WW, Jans JJM, van Beers EJ, van Wijk R. Metabolic blood profile and response to treatment with the pyruvate kinase activator mitapivat in patients with sickle cell disease. Hemasphere. 2024 Jun 25;8(6):e109
Rab MAE, Kanne CK, Boisson C, Bos J, van Oirschot BA, Houwing ME, Renoux C, Bartels M, Anita Rijneveld, Nur E, Cnossen MH, Joly P, Nader E, Fort R, Connes P, van Wijk R, Sheehan VA, van Beers EJ. Oxygen gradient ektacytometry-derived biomarkers are associated with acute complications in sickle cell disease. Blood Adv. 2024 Jan 23;8(2):276-286.